Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

21 Mar 2019 09:18

RNS Number : 5730T
Frontier IP Group plc
21 March 2019
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

21 March 2019

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Trading update

 

Frontier IP, a specialist in commercialising university intellectual property, is pleased to provide an update on trading for the year ending 30 June 2019.

 

The Group has enjoyed a strong first half to the financial year and since the beginning of 2019 there have been a number of positive portfolio updates as previously announced by the Group. In addition, Frontier IP has earlier today announced that Exscientia, a world leader in AI-driven drug discovery, has secured a significant trade deal with Celgene Corporation. This, combined with other progress Exscientia is making, is expected to result in a substantial uplift in Frontier IP's book value for its holding.

 

Whilst it is not possible for the Board to be certain on what the overall portfolio valuation will be at 30 June 2019 and progress of early and development stage businesses that constitute Frontier IP's portfolio is inherently uncertain, based on the trading for the year to date and the outlook for the remainder of the financial year the Board anticipates that the outcome for the year ending 30 June 2019 will be ahead of management expectations.

 

The Group will be releasing its interim results for the six months to 31 December 2018 by end of March 2019.

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive Officer

Andrew Johnson, Communications & Investor Relations

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas

 

Nicholas Chambers

 

 

ABOUT FRONTIER IP: www.frontierip.co.uk

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUAAKRKNAOURR
Date   Source Headline
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.